Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Houston, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Longview, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Longview, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Midland, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Midland, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
San Antonio, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Temple, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Tyler, TX
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Alexandria, VA
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
mi
from
Antwerpen,
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
mi
from
Antwerpen,
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
mi
from
Washington, D.C.,
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
CD123 Redirected Autologous T Cells for AML
Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated:  10/13/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
CD123 Redirected Autologous T Cells for AML
Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated: 10/13/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  10/13/2017
Stanford University
mi
from
Stanford, CA
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 10/13/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Status: Enrolling
Updated:  10/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Status: Enrolling
Updated: 10/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated:  10/16/2017
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated: 10/16/2017
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated:  10/16/2017
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated: 10/16/2017
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated:  10/16/2017
Duke Univ Med Ctr
mi
from
Durham, NC
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated: 10/16/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated:  10/16/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated: 10/16/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated:  10/16/2017
University of Massachusettes Memorial
mi
from
Worcester, MA
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma
Status: Enrolling
Updated: 10/16/2017
University of Massachusettes Memorial
mi
from
Worcester, MA
Click here to add this to my saved trials
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  10/16/2017
University Park Hematology Oncology
mi
from
Englewood, CO
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 10/16/2017
University Park Hematology Oncology
mi
from
Englewood, CO
Click here to add this to my saved trials
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  10/16/2017
Cleveland Clinic Florida
mi
from
Weston, FL
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 10/16/2017
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  10/16/2017
Maine Cancer Center of Medicine
mi
from
Scarborough, ME
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 10/16/2017
Maine Cancer Center of Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  10/16/2017
Research Site
mi
from
Melbourne,
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 10/16/2017
Research Site
mi
from
Melbourne,
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
City of Hope
mi
from
Duarte, CA
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Stanford Cancer Institute
mi
from
Stanford, CA
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Stanford Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Boston University Medical Center
mi
from
Boston, MA
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Columbia University
mi
from
New York, NY
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Duke Univ Med Ctr
mi
from
Durham, NC
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Oregon Health and Sciences University
mi
from
Portland, OR
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated:  10/16/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Status: Enrolling
Updated: 10/16/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  10/16/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 10/16/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients
Status: Enrolling
Updated:  10/17/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients
Status: Enrolling
Updated: 10/17/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated:  10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations
Status: Enrolling
Updated: 10/17/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy
Status: Enrolling
Updated:  10/17/2017
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
mi
from
Little Rock, AR
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy
Status: Enrolling
Updated: 10/17/2017
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Arizona Oncology
mi
from
Tucson, AZ
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Arizona Oncology
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Rocky Mountain Cancer Centers, LLP
mi
from
Aurora, CO
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Rocky Mountain Cancer Centers, LLP
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Massachusetts General Hospital - Oncology
mi
from
Boston, MA
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Massachusetts General Hospital - Oncology
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Washington University
mi
from
Saint Louis, MO
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Vanderbilt
mi
from
Nashville, TN
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated:  10/17/2017
Tianjin Cancer Hospital
mi
from
Tianjin,
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Status: Enrolling
Updated: 10/17/2017
Tianjin Cancer Hospital
mi
from
Tianjin,
Click here to add this to my saved trials
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas (UARK 2001-12), A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma
Status: Enrolling
Updated:  10/17/2017
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas (UARK 2001-12), A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma
Status: Enrolling
Updated: 10/17/2017
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Click here to add this to my saved trials
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
Preemptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-free on Total Therapy 2 (UARK 98-026)
Status: Enrolling
Updated:  10/17/2017
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
mi
from
Little Rock, AR
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
Preemptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-free on Total Therapy 2 (UARK 98-026)
Status: Enrolling
Updated: 10/17/2017
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
mi
from
Little Rock, AR
Click here to add this to my saved trials